Elan/Wyeth Move Novel Alzheimer’s Treatment Into Phase III
This article was originally published in The Pink Sheet Daily
Monoclonal antibody’s influence on beta amyloid in the brain could be disease-modifying.
You may also be interested in...
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.